CAMP4 Therapeutics Corporation
$3.39 +$0.23 (+7.28%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
A material event was filed (Form 8-K).
8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 23
From its Mar 9 high, the share price fell 52%.
Peak close $6.28 on Mar 9; trough close $3.01 on Jul 23. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -52% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Mar 9
The stock moved +49.4% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 9 -
Feb 9
The stock moved +12.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 9
The story updates itself as events post · The wolf reports; you decide
Snapshot
About CAMP4 Therapeutics Corporation
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.